On Sept. 19, Rising Pharma Holdings Inc. announced the opening of a commercial manufacturing facility in Decatur, Ill., to manufacture and package sterile products, including injectables and ophthalmic products in response to critical pharmaceutical supply shortages in the U.S. The site comprises a manufacturing and packaging facility spanning a combined 230,000 square feet. The move is expected to augment Rising’s existing product portfolio and offer a wider basket of products for customers.
“Rising Pharmaceuticals is proud to play a significant role supporting the healthcare system by producing more than 180 commercialized generic medicines and over 620 active SKUs on the market. With one of the broadest portfolios of any U.S. generic pharmaceuticals company, we recognize that expanding manufacturing capabilities in the U.S. is mission-critical for our continued commercial success, as well as for public health in general,” said Vimal Kavuru, CEO of Rising Pharmaceuticals. “The new facility will adhere to stringent quality standards to produce generic medications that are effective and cost-efficient.”
“We look forward to creating a model of sustainable development through our partnership with the Decatur community, balancing efficient U.S. manufacturing growth while competing in the global pharmaceutical supply chain,” said Steven Coventry, vice president of operations and general manager, Rising Pharmaceuticals. “Our facility is reemerging from a prior closure and has been a staple of the Decatur community since 1952. We anticipate that the new site will help create jobs, economic growth, and enhance healthcare accessibility.”